Cherian, J. J. Et Al. 2015. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. OSTEOARTHRITIS AND CARTILAGE , vol.23, no.12 , 2109-2118.

Cherian, J. J., PARVİZİ, J., Bramlet, D., Lee, K. H., Romness, D. W., & Mont, M. A., (2015). Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee. OSTEOARTHRITIS AND CARTILAGE , vol.23, no.12, 2109-2118.

Cherian, J. Et Al. "Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee," OSTEOARTHRITIS AND CARTILAGE , vol.23, no.12, 2109-2118, 2015

Cherian, J. J. Et Al. "Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee." OSTEOARTHRITIS AND CARTILAGE , vol.23, no.12, pp.2109-2118, 2015

Cherian, J. J. Et Al. (2015) . "Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee." OSTEOARTHRITIS AND CARTILAGE , vol.23, no.12, pp.2109-2118.

@article{article, author={J. J. Cherian Et Al. }, title={Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β1 in patients with grade 3 chronic degenerative joint disease of the knee}, journal={OSTEOARTHRITIS AND CARTILAGE}, year=2015, pages={2109-2118} }